Psychedelics in Addiction Treatment

Credit

Handouts

Faculty

Chantelle Thomas, PhD Related seminars and products

---

Dr. Chantelle Thomas is a clinical psychologist and executive clinical director of Windrose Recovery – a multi-level residential addiction treatment program offering detoxification, intensive outpatient programming, and integrated ketamine-assisted psychotherapy. Dr. Thomas has been directly involved in clinical research trials at the University of Wisconsin School of Medicine and Public Health investigating the clinical use of psychedelics for over nine years. Current trials include the study of psilocybin for addiction and depression and MDMA for PTSD. She currently serves as a supervisor and trainer on the MAPS sponsored clinical trials of MDMA-assisted psychotherapy for PTSD for US and European clinical trials and Expanded Access Program. Dr. Thomas completed a postdoctoral fellowship in health psychology at the University of Wisconsin School of Medicine and Public Health and is a certified biofeedback practitioner. Her areas of specialization include chronic pain, trauma-related disorders, substance use disorders, and psychedelic integration.

Speaker Disclosures:
Financial: Dr. Chantelle Thomas has employment relationships with Integrata Healing, Windrose Recovery, The Manor, Dane County, and the University of Wisconsin. She receives a consulting fee from Usona Institute, Lykos, Polaris Institute, and MindMed. Dr. Thomas is a trainer with Fluence Training and a podcast host of Blind Spots. She is a therapist who is working on a clinical trial sponsored by Revive Therapeutics and Beckley Ltd. Dr. Thomas receives a speaking honorarium from Psychotherapy Networker and PESI, Inc. All relevant financial relationships with ineligible organizations have been mitigated.
Non-financial: Dr. Chantelle Thomas has no relevant non-financial relationships.

Additional Info

Access never expires for this product.

For a more detailed outline that includes times or durations of time, if needed, please contact cepepesi.com

Visit our FAQ page at www.pesi.com/faq or contact us at www.pesi.com/info

Objectives

1. Identify psychedelic compounds and their clinical indications based on currently available treatment versus those currently under investigation.  
2. Compare mechanistic considerations in existing and proposed treatment models involving psychedelics.   
3. Examine the importance of informed consent and client selection related to psychedelic treatment.    

Outline

Transforming Addiction Therapy with Cutting-Edge Psychedelic Research: Brief Overview 

• The role of psychedelics in addiction treatment 
• Importance of understanding evidence, safety, and therapeutic contexts 
• Psychedelic Compounds and Clinical Indications: Overview 

Different Psychedelic Compounds 

• Classic psychedelics (e.g., psilocybin, LSD) 
• Empathogens (e.g., MDMA) 
• Dissociatives (e.g., ketamine) 

Clinical Indications 

• Current FDA-approved treatments 
• Compounds under investigation 
• Potential future applications 

Mechanistic Considerations in Psychedelic Treatment Models 

• Existing Treatment Models 
  • Mechanisms of action in approved therapies 
  • Clinical outcomes and case studies 
• Proposed Treatment Models 
  • Emerging research and hypotheses 
  • Comparative analysis of mechanisms in various models 

The “Set and Setting” Approach 

• Importance of “Set and Setting” 
  • Psychological mindset (set) 
  • Physical and social environment (setting) 
• Optimizing Therapeutic Potential 
  • Techniques to enhance set and setting 
  • Case studies and practical examples 
• Paradigm Shifts 
  • Changes in therapeutic practices 
  • Integration of non-ordinary states of consciousness 

Informed Consent and Client Selection 

• Importance of Informed Consent 
  • Key elements of informed consent in psychedelic therapy 
  • Ethical considerations 
• Client Selection 
  • Criteria for selecting suitable candidates 
  • Screening and assessment processes 
• Risks and Benefits 
  • Identifying potential risks 
  • Strategies to maximize benefits and minimize harm 

Future directions in psychedelic treatment for addiction 

Target Audience

• Addiction Professionals 
• Case Managers 
• Dieticians 
• Licensed Clinical/Mental Health Counselors 
• Marriage & Family Therapists 
• Nurses 
• Psychologists 
• Social Workers